Would you use a NTRK TKI for a patient with metastatic HR+, HER2- breast cancer with a complex NTRK3 gene re-arrangement on Foundation testing?

ie, not a classic NTRK3-ETV6 fusion.The patient has progressed through CDk4/6 inhibitors and intolerant of alpelisib, and does not want chemotherapy.

Answer from: Medical Oncologist at Academic Institution

While it's difficult to give an answer without knowing details of the fusion event, I would point to the potential for immunohistochemistry for Trk as an orthogonal method for identifying Trk expressing cancers with potential for testing Trk inhibitors. I would point to this paper for further inform...

Comments

Medical Oncologist at Cancer Care Specialists/Renown Oncology/UNR
You can ask FoundationOne to interpret the data an...

Please select the option that best describes you:

Would you use a NTRK TKI for a patient with metastatic HR+, HER2- breast cancer with a complex NTRK3 gene re-arrangement on Foundation testing?

Related Questions